Form D · Biotechnology
Geom Therapeutics, Inc.
San Francisco, CA · CIK 0001702693
Offering snapshot reported Apr 11, 2017 · SEC filing
- Reported sold
- $4.36M Offering amount: $4.5M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 9, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 11, 2017 | Initial | $4,355,000 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-284519
Series A Preferred Stock and Common Stock issuable upon conversion
Source: Form D, filed Apr 11, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cooper Collins | Director |
| Dov Goldstein | Director |
| Yong Zu Kim | Director |
| Sejin Park | Director |
| Dirk Thye | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
826 A Vallejo Street
San Francisco, CA, 94133
San Francisco, CA, 94133